Milestone Pharmaceuticals Inc. Common Shares (MIST) Dividend History

Company News

• Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China

  Milestone Pharmaceuticals' licensing partner Ji Xing Pharmaceuticals announced positive results from a Phase 3 trial of etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia (PSVT) in China. The trial met its primary endpoint, with a significantly greater proportion of patients treated with etripamil converting from PSVT to sinus rhythm within 30 minutes compared to placebo.

  GlobeNewswire Inc.
• Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors

  Milestone Pharmaceuticals announced the appointment of Joseph Papa, a renowned pharmaceutical and healthcare leader, to its Board of Directors. Papa's extensive experience in the industry is expected to provide strategic guidance as Milestone prepares for the potential approval of its investigational drug CARDAMYST for the treatment of paroxysmal supraventricular tachycardia.

  GlobeNewswire Inc.

  Featured Companies: BLCO CADL EBS PRGO
• Milestone Pharmaceuticals to Host KOL Event for Investors “Learnings from the Field: Expert Perspectives on PSVT in the Community Setting” on June 20, 2024

  MONTREAL and CHARLOTTE, N.C., June 12, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will host Part I of its virtual investor educational series on Thursday, June 20, 2024, at 8:00 AM ET. To register for “Learnings from the Field: Expert Perspectives on Managing PSVT in the Community Setting,” click here.

  GlobeNewswire Inc.
• Milestone® Pharmaceuticals to Participate in the Upcoming Jefferies Global Healthcare Conference

  MONTREAL and CHARLOTTE, N.C., May 31, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will participate in the Jefferies Global Healthcare Conference being held in New York City, NY from June 4-6, 2024.

  GlobeNewswire Inc.
• Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST™

  MONTREAL and CHARLOTTE, N.C., May 29, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that the United States Food and Drug Administration (FDA) accepted the Company’s New Drug Application (NDA) on May 26, 2024 for CARDAMYST (etripamil) nasal spray, its lead investigational product for the management of paroxysmal supraventricular tachycardia (PSVT). The FDA Prescription Drug User Fee Act (PDUFA) target date is 10 months from the acceptance date of May 26, 2024.

  GlobeNewswire Inc.